Schellenberg Wittmer advised Santhera on the sale of its Raxone®/Idebenone business
31.07.2023
Schellenberg Wittmer advised Santhera Pharmaceuticals Holding AG on the sale of its Raxone®/idebenone business for all indications worldwide to Chiesi Farmaceutici S.p.A. The transaction replaces the existing license …
Schellenberg Wittmer acted as co-counsel for Sosei Heptares
20.07.2023
Schellenberg Wittmer acted as co-counsel for Sosei Heptares on its acquisition of Idorsia Pharmaceuticals Ltd's pharmaceuticals business in Japan and APAC.
Contact
Vibeke Berning Johansen
Head of Marketing & Communications
Schellenberg Wittmer advised Swisscanto Private Equity on the Series B financing of Distran
23.06.2023
Schellenberg Wittmer advised Swisscanto Private Equity in the CHF 8.3 million Series B financing of the leading innovator in ultrasonic camera technology Distran.
Schellenberg Wittmer advises Sentinal Group on financing of European helicopter leasing platform
23.06.2023
Schellenberg Wittmer advised Sentinal Leasing AG on its latest ordinary capital increase with a total issue amount of CHF 20 million as well as on the financing of …
Schellenberg Wittmer advises Santhera on license for North America for Vamorolone
20.06.2023
Santhera Pharmaceuticals (SIX: SANN) has signed an exclusive license and collaboration agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX).